 | • レポートコード：20QY06-04965 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、癌治療用チェックポイント阻害剤のグローバル市場について種類別（PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤）、用途別（黒色腫治療、膀胱がん治療、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・癌治療用チェックポイント阻害剤市場の概要 ・世界の主要地域別癌治療用チェックポイント阻害剤市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の癌治療用チェックポイント阻害剤市場規模2015-2026：種類別（PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤） ・世界の癌治療用チェックポイント阻害剤市場規模2015-2026：用途別（黒色腫治療、膀胱がん治療、その他） ・癌治療用チェックポイント阻害剤の北米市場規模2015-2020 ・癌治療用チェックポイント阻害剤のヨーロッパ市場規模2015-2020 ・癌治療用チェックポイント阻害剤の中国市場規模2015-2020 ・癌治療用チェックポイント阻害剤の日本市場規模2015-2020 ・癌治療用チェックポイント阻害剤の東南アジア市場規模2015-2020 ・癌治療用チェックポイント阻害剤のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Bristol-Myers Squibb(BMS)、Merck、Roche） ・癌治療用チェックポイント阻害剤の製造コスト分析 ・販売チャネル、流通業者、顧客 ・癌治療用チェックポイント阻害剤の市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Checkpoint Inhibitors for Treating Cancer Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Checkpoint Inhibitors for Treating Cancer market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Checkpoint Inhibitors for Treating Cancer market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Checkpoint Inhibitors for Treating Cancer industry.
Based on our recent survey, we have several different scenarios about the Checkpoint Inhibitors for Treating Cancer YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 7551.9 million in 2019. The market size of Checkpoint Inhibitors for Treating Cancer will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Checkpoint Inhibitors for Treating Cancer market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Checkpoint Inhibitors for Treating Cancer market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Checkpoint Inhibitors for Treating Cancer market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Checkpoint Inhibitors for Treating Cancer market. The report also includes nautical information, where it shows Checkpoint Inhibitors for Treating Cancer market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Checkpoint Inhibitors for Treating Cancer market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Checkpoint Inhibitors for Treating Cancer market.
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Geographical Analysis:
Based on region, the global Checkpoint Inhibitors for Treating Cancer market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Checkpoint Inhibitors for Treating Cancer market are
Bristol-Myers Squibb(BMS)
Merck
Roche
…
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Checkpoint Inhibitors for Treating Cancer market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Checkpoint Inhibitors for Treating Cancer market.
• The market share of the global Checkpoint Inhibitors for Treating Cancer market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Checkpoint Inhibitors for Treating Cancer market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Checkpoint Inhibitors for Treating Cancer market.
1 Checkpoint Inhibitors for Treating Cancer Market Overview
1.1 Checkpoint Inhibitors for Treating Cancer Product Scope
1.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2026)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Checkpoint Inhibitors for Treating Cancer Segment by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Comparison by Application (2020-2026)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Checkpoint Inhibitors for Treating Cancer Market Estimates and Forecasts (2015-2026)
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2026)
1.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2026)
1.4.3 Global Checkpoint Inhibitors for Treating Cancer Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Checkpoint Inhibitors for Treating Cancer Industry Impact
1.5.1 How the Covid-19 is Affecting the Checkpoint Inhibitors for Treating Cancer Industry
1.5.1.1 Checkpoint Inhibitors for Treating Cancer Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Checkpoint Inhibitors for Treating Cancer Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Checkpoint Inhibitors for Treating Cancer Players to Combat Covid-19 Impact
2 Checkpoint Inhibitors for Treating Cancer Estimate and Forecast by Region
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
2.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
2.3 Global Checkpoint Inhibitors for Treating Cancer Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2015-2026)
2.4.2 Europe Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2015-2026)
2.4.3 China Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2015-2026)
2.4.4 Japan Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2015-2026)
2.4.6 India Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2015-2026)
3 Global Checkpoint Inhibitors for Treating Cancer Competition Landscape by Players
3.1 Global Top Checkpoint Inhibitors for Treating Cancer Players by Sales (2015-2020)
3.2 Global Top Checkpoint Inhibitors for Treating Cancer Players by Revenue (2015-2020)
3.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2019)
3.4 Global Checkpoint Inhibitors for Treating Cancer Average Price by Company (2015-2020)
3.5 Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Checkpoint Inhibitors for Treating Cancer Players (Opinion Leaders)
4 Global Checkpoint Inhibitors for Treating Cancer Market Size by Type
4.1 Global Checkpoint Inhibitors for Treating Cancer Historic Market Review by Type (2015-2020)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2015-2020)
4.1.3 Global Checkpoint Inhibitors for Treating Cancer Price by Type (2014-2020)
4.2 Global Checkpoint Inhibitors for Treating Cancer Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2021-2026)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2021-2026)
4.2.3 Global Checkpoint Inhibitors for Treating Cancer Price Forecast by Type (2021-2026)
5 Global Checkpoint Inhibitors for Treating Cancer Market Size by Application
5.1 Global Checkpoint Inhibitors for Treating Cancer Historic Market Review by Application (2015-2020)
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2015-2020)
5.1.3 Global Checkpoint Inhibitors for Treating Cancer Price by Application (2015-2020)
5.2 Global Checkpoint Inhibitors for Treating Cancer Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2021-2026)
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2021-2026)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Price Forecast by Application (2021-2026)
3 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures
3.2 North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
3.3 North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
3.4 North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
4 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures
4.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
4.4 Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
5 China Checkpoint Inhibitors for Treating Cancer Market Facts & Figures
5.2 China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
5.3 China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
5.4 China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
6 Japan Checkpoint Inhibitors for Treating Cancer Market Facts & Figures
6.2 Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
6.3 Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
6.4 Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
7 Southeast Asia Checkpoint Inhibitors for Treating Cancer Market Facts & Figures
7.2 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
8 India Checkpoint Inhibitors for Treating Cancer Market Facts & Figures
8.2 India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
8.3 India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
8.4 India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Checkpoint Inhibitors for Treating Cancer Business
12.1 Bristol-Myers Squibb(BMS)
12.1.1 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Corporation Information
12.1.2 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Business Overview and Total Revenue
12.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
12.1.5 Bristol-Myers Squibb(BMS) Recent Development
12.2 Merck
12.2.1 Merck Checkpoint Inhibitors for Treating Cancer Corporation Information
12.2.2 Merck Checkpoint Inhibitors for Treating Cancer Business Overview and Total Revenue
12.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
12.2.5 Merck Recent Development
12.3 Roche
12.3.1 Roche Checkpoint Inhibitors for Treating Cancer Corporation Information
12.3.2 Roche Checkpoint Inhibitors for Treating Cancer Business Overview and Total Revenue
12.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
12.3.5 Roche Recent Development
…
13 Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Analysis
13.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
13.4 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Checkpoint Inhibitors for Treating Cancer Distributors List
14.3 Checkpoint Inhibitors for Treating Cancer Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Growth Rate by Type (2020-2026)
Table 2. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Checkpoint Inhibitors for Treating Cancer Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Checkpoint Inhibitors for Treating Cancer Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Checkpoint Inhibitors for Treating Cancer Players to Combat Covid-19 Impact
Table 8. Global Market Checkpoint Inhibitors for Treating Cancer Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Region (2015-2020)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Region (2015-2020)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Forecast by Region (2021-2026)
Table 14. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Revenue Share Forecast by Region (2021-2026)
Table 17. Global Checkpoint Inhibitors for Treating Cancer (g) of Key Companies (2015-2020)
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Company (2015-2020)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Company (2015-2020)
Table 21. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2019)
Table 22. Global Checkpoint Inhibitors for Treating Cancer Average Price (USD/mg) of Key Company (2015-2020)
Table 23. Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Sites and Area Served
Table 24. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Checkpoint Inhibitors for Treating Cancer Players
Table 27. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2015-2020)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Price (g) by Type (2015-2020)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2021-2026)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2021-2026)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Price (g) by Type (2021-2026)
Table 35. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 36. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2015-2020)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Price (g) by Application (2015-2020)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2021-2026)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2021-2026)
Table 41. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2021-2026)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Price (g) by Application (2021-2026)
Table 44. United States Checkpoint Inhibitors for Treating Cancer Sales (g) by Company (2015-2020)
Table 45. United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
Table 46. United States Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 47. United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 48. United States Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 49. United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 50. Europe Checkpoint Inhibitors for Treating Cancer Sales (g) by Company (2015-2020)
Table 51. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
Table 52. Europe Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 53. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 54. Europe Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 55. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 56. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Company (2015-2020)
Table 57. China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
Table 58. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 59. China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 60. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 61. China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 62. Japan Checkpoint Inhibitors for Treating Cancer Sales (g) by Company (2015-2020)
Table 63. Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
Table 64. Japan Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 65. Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 66. Japan Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 67. Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales (g) by Company (2015-2020)
Table 69. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 71. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 73. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 74. India Checkpoint Inhibitors for Treating Cancer Sales (g) by Company (2015-2020)
Table 75. India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2015-2020)
Table 76. India Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 77. India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 78. India Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 79. India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 80. Bristol-Myers Squibb(BMS) Corporation Information
Table 81. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 82. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million USD), Price (USD/mg) and Gross Margin (2015-2020)
Table 83. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
Table 84. Bristol-Myers Squibb(BMS) Recent Development
Table 85. Merck Corporation Information
Table 86. Merck Description and Business Overview
Table 87. Merck Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million USD), Price (USD/mg) and Gross Margin (2015-2020)
Table 88. Merck Checkpoint Inhibitors for Treating Cancer Product
Table 89. Merck Recent Development
Table . Roche Corporation Information
Table . Roche Description and Business Overview
Table . Roche Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million USD), Price (USD/mg) and Gross Margin (2015-2020)
Table . Roche Checkpoint Inhibitors for Treating Cancer Product
Table . Roche Recent Development
Table 95. Production Base and Market Concentration Rate of Raw Material
Table 96. Key Suppliers of Raw Materials
Table 97. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 98. Checkpoint Inhibitors for Treating Cancer Customers List
Table 99. Market Key Trends
Table 100. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 101. Key Challenges
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2020 & 2026
Figure 6. Melanoma Treatment Examples
Figure 7. Bladder Cancer Treatment Examples
Figure 8. Other Examples
Figure 9. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Growth Rate (2015-2026)
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Price Trends Growth Rate (2015-2026) (USD/mg)
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Checkpoint Inhibitors for Treating Cancer Sales (g) Growth Rate (2015-2026)
Figure 16. Europe Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Checkpoint Inhibitors for Treating Cancer Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Checkpoint Inhibitors for Treating Cancer Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Checkpoint Inhibitors for Treating Cancer Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Checkpoint Inhibitors for Treating Cancer Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue in Checkpoint Inhibitors for Treating Cancer 2015 & 2019
Figure 27. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2015-2020)
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2015-2020)
Figure 31. Global Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 33. United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 34. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2019
Figure 35. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 36. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 37. China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2019
Figure 38. China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 39. China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 40. Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2019
Figure 41. Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 42. Japan Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 43. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2019
Figure 44. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 45. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 46. India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2019
Figure 47. India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 48. India Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 49. Bristol-Myers Squibb(BMS) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Key Raw Materials Price Trend
Figure 53. Manufacturing Cost Structure of Checkpoint Inhibitors for Treating Cancer
Figure 54. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 55. Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Porter's Five Forces Analysis
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
がんCDK阻害剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Cancer CDK Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cancer CDK Inhibitors m…- 腫瘍治療フィールド（TTFields）の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Tumor Treating Fields (TTFields) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tumor Treati…
- スケール防止剤/スケール抑制剤の世界市場レポート2020 Market Analysis and Insights: Global Antiscalants/Scale Inhibitors Market The global Antiscalants/Scale Inhibitors market was valued at US$ 2326.5 million in 2019 and will reach US$ 2805.9 million by the end of 2026, growing at a CAGR of 2.7% during 2020-2026. Global Antiscalants/Scale Inhibitors Sc…
- パラフィン阻害剤の世界市場レポート2020 Paraffin inhibitors can prevent waxes from depositing on cold surfaces such as pipeline walls. The deposition of paraffin from oil is expected to be the dominant factor driving the paraffin ihibitors market. Market Analysis and Insights: Global Paraffin Inhibitors Market The global Paraffin Inhibito…
- カビ防止剤の世界市場レポート2020 The global mold inhibitors market has high growth prospects, and has the potential to offer innumerable opportunities to new entrants in this market. Rising health-consciousness and more focused research & development in the pharmaceutical industry has increased the market share of this application …